However, alterations in PREX2 were observed in 23 out of 103 patients, including hyper-methylation of promoter regions in 15 patients (Fig. 1c, d, Fig. S4a), which had not been reported in ESCC previously. Here, PREX2 is linked to esophageal squamous cell carcinoma.